🔴 IBRX is trading 4.2% down today as profit-taking extends after FDA sBLA acceptance rally

IBRX is trading 4.2% down at $7.42 as traders extend profit-taking following the sharp FDA sBLA acceptance rally linked to ANKTIVA plus BCG.

• The stock continues its retreat after falling 3.9% on May 21, 2026, amid high-volume repositioning.
• The move appears to be stock-specific consolidation rather than macro-driven pressure, as the decline occurs while major U.S. indices are trading higher.